Article
Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.
The Clinical investigator - 1 Dec 1994
Hansen P S, Meinertz H, Gerdes L U, Klausen I C, Faergeman O
Abstract excerpt
Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.